Pdt Partners, LLC Seagen Inc. Transaction History

Pdt Partners, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$117.37 - $139.17 $1.47 Million - $1.75 Million	12,560 Added 195.09%	18,998 $2.44 Million
Q3 2022 Nov 14, 2022	BUY	$135.27 - $180.11 $870,868 - $1.16 Million	6,438 New	6,438 $881,000
Q1 2022 May 16, 2022	SELL	$119.61 - $157.85 $322,947 - $426,195	-2,700 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$142.57 - $190.86 $384,939 - $515,322	2,700 New	2,700 $417,000
Q2 2021 Aug 16, 2021	SELL	$135.08 - $161.1 $4.11 Million - $4.9 Million	-30,413 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$137.51 - $190.8 $640,246 - $888,364	-4,656 Reduced 13.28%	30,413 $4.22 Million
Q4 2020 Feb 16, 2021	BUY	$164.63 - $211.93 $5.77 Million - $7.43 Million	35,069 New	35,069 $6.14 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Pdt Partners, LLC with notifications on news.